Kenvue Inc. (NYSE:KVUE) Shares Sold by Crestwood Advisors Group LLC

Crestwood Advisors Group LLC reduced its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 3.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,489,104 shares of the company's stock after selling 48,244 shares during the quarter. Crestwood Advisors Group LLC owned about 0.08% of Kenvue worth $34,443,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Yacktman Asset Management LP lifted its position in Kenvue by 2.9% during the 3rd quarter. Yacktman Asset Management LP now owns 8,381,404 shares of the company's stock worth $193,862,000 after acquiring an additional 232,631 shares during the period. National Pension Service lifted its holdings in shares of Kenvue by 14.5% during the third quarter. National Pension Service now owns 2,829,772 shares of the company's stock worth $65,453,000 after purchasing an additional 357,672 shares during the period. Cohen Capital Management Inc. boosted its position in Kenvue by 1.6% in the third quarter. Cohen Capital Management Inc. now owns 168,193 shares of the company's stock valued at $3,890,000 after buying an additional 2,640 shares during the last quarter. CORDA Investment Management LLC. increased its holdings in Kenvue by 1.3% in the 3rd quarter. CORDA Investment Management LLC. now owns 1,235,630 shares of the company's stock worth $28,580,000 after buying an additional 16,270 shares during the period. Finally, Allen Wealth Management LLC raised its position in Kenvue by 14.4% during the 3rd quarter. Allen Wealth Management LLC now owns 76,558 shares of the company's stock worth $1,771,000 after buying an additional 9,618 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE stock traded up $0.19 during trading hours on Tuesday, reaching $23.23. The company had a trading volume of 17,779,775 shares, compared to its average volume of 18,105,982. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The stock has a fifty day moving average of $22.57 and a 200-day moving average of $20.47. The company has a market capitalization of $44.48 billion, a price-to-earnings ratio of 40.04, a PEG ratio of 2.97 and a beta of 1.36. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $23.57.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company had revenue of $4 billion during the quarter, compared to analysts' expectations of $3.93 billion. During the same quarter last year, the firm earned $0.32 earnings per share. The firm's quarterly revenue was down .3% compared to the same quarter last year. On average, equities analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.53%. Kenvue's dividend payout ratio (DPR) is presently 141.38%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on KVUE shares. Royal Bank of Canada lowered Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective for the company. in a research note on Tuesday, September 24th. Citigroup decreased their price target on Kenvue from $21.00 to $20.00 and set a "neutral" rating for the company in a report on Wednesday, July 10th. JPMorgan Chase & Co. raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Finally, Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.